The Impact of Risk Reduction Initiatives on Chronic Opioid Use
Improving the way opioid medications are prescribed — through clinical practice guidelines and opioid risk reduction strategies — may improve overall drug efficacy and limit use of higher opioid doses
Exposing clinicians to a multifaceted risk-reduction initiative significantly shifts prescribing practices away from high-dose chronic opioid therapy, according to a study published in the Journal of Pain.
Such interventions are sorely needed; prescription opioid sales in the United States have tripled since 1999, though the amount of chronic pain reported by patients remains unchanged. The explosion in opioid use was accompanied by repercussions — nearly 2 million American teens and adults either abused or were dependent on opioid pain relievers in 2013, and the number of overdoses had quadrupled to over 16,000.1
"There is no evidence that the effectiveness of opioids for managing chronic pain increases with dose, but there is now substantial evidence that risks of overdose and addiction increase with dose," lead author Michael Von Korff, ScD, from the Group Health Research Institute in Seattle, Washington, told Clinical Pain Advisor.
Improving the way opioid medications are prescribed — through clinical practice guidelines and opioid risk reduction strategies — may improve overall drug efficacy and limit use of higher opioid doses. Adopting such measures may also reduce the risks for serious adverse events and drug opioid misuse, abuse, and diversion.
"Policy changes [with respect to prescribing chronic opioid therapy] are now taking place across the country. Clinicians should be prepared to implement them, [and] be vigilant to ensure that they do, indeed, produce the intended results," Bob Twillman, PhD, executive director of the American Academy of Pain Management in Sonora, California, told Clinical Pain Advisor.
Multi-Pronged Initiatives Curb Opioid Prescribing
To determine whether combining risk mitigation initiatives would yield greater dose reductions, Dr. Von Korff and colleagues examined prescription data for 22,205 patients using chronic opioid therapy (COT) — 16,653 from clinicians in group practice, and 5,552 in contracted care.2
As controls, clinicians for the contracted care group were exposed only to initiatives implemented by Washington State in in 2010, which recommended caution in prescribing COT at higher doses, defined as daily morphine equivalent dose (MED) of 120 mg or greater.